Medtronic Reports Strong Q1 FY27 Results and Raises Guidance

Details

The company reported GAAP diluted EPS of $1.14 and non-GAAP diluted EPS of $1.45, ahead of guidance. Medtronic raised its FY27 organic revenue growth guidance to 7.25% to 7.75% and its FY27 diluted non-GAAP EPS guidance to the new range of $5.94 to $6.00. The company's strong performance across all segments, including Cardiovascular, Neuroscience, and Medical Surgical, supported the guidance update.

Items reported

About Medtronic plc

Medtronic plc is a leading global healthcare technology company that designs, manufactures, and sells innovative medical devices and therapies used in various medical procedures. The primary function of Medtronic is to improve healthcare outcomes by providing advanced therapeutic solutions. Its extensive product portfolio includes cardiac and vascular devices, diabetes-related products, minimally invasive therapies, and neurosurgical technologies. Medtronic plays a vital role in the medical device industry, catering to cardiovascular treatment, advanced diabetes management, spinal and musculoskeletal therapy, and more. Notably, the company is renowned for its pacemaker technology and is a pivotal player in cardiac care. The company's innovations significantly impact the healthcare sector by enhancing the quality of life for patients worldwide and improving the effectiveness of medical treatments. As a key player in the medical device market, Medtronic is instrumental in setting industry standards and advancing medical technology through continuous research and development. Founded in 1949 and headquartered in Dublin, Ireland, Medtronic's global presence underscores its substantial contribution to the healthcare industry across various continents.